In vitro inhibitory activity against [3H](2S)-2-[4-(3-azidophenyl)-2-oxopyrrolidin-1-yl]butanamide binding to levetiracetam binding site
C1CC(=O)N(C1)CC(=O)N,2.51189e+13
CCCC1(CC(=O)N(C1)C(CC)C(=O)N)C,2.51189e+15
CCC(C(=O)N)N1CC(CC1=O)CC2CC2,7.94328e+15
CCC(C(=O)N)N1C(=O)CCC1(C)C,1.58489e+13
CCC(C(=O)NO)N1CCCC1=O,5.01187e+14
CC(C(=O)N)N1CCCC1=O,3.16228e+14
CCC(C(=O)N)N1CCCC1=O,1.25893e+15
CCC(C(=O)N)N1CC(CC1=O)CC2=CC=CC=C2,3.98107e+14
CCC1CC(=O)N(C1)C(CC)C(=O)N,7.94328e+14
CCC(C(=O)N)N1CC(CC1=O)C(C)C,2.51189e+14
CC(C)C(C(=O)N)N1CCCC1=O,5.01187e+13
CCC(C(=O)N)N1CC(CC1=O)COC,6.30957e+14
CCCCCCCN(C(CC)C(=O)N)C(=O)CC1=CC=C(C=C1)OC,3.98107e+14
CCCCCN(C(CC)C(=O)N)C(=O)CC,5.01187e+14
CCC(C(=O)N)N1CC(CC1=O)CC(C)(C)C,1.25893e+15
CCC(C(=O)N)N1CC(CC1=O)CCl,5.01187e+15
CCC(C(=O)N)N1CC(CC1=O)CF,7.94328e+14
CCCCN(C(CC)C(=O)N)C(=O)CC,1e+14
CCC(C(=O)N)N(C)C(=O)C,6.30957e+13
CCCCCCCCN(C(CC)C(=O)N)C(=O)CC,2.51189e+14
CCC(C(=O)N)N1CC2(CCC2)CC1=O,5.01187e+14
CCCCCC1CC(=O)N(C1)C(CC)C(=O)N,7.94328e+14
CCC(C(=O)N)N1CC(CC1=O)CI,6.30957e+15
CCC(C(=O)N)N1CC(CC1=O)CBr,3.98107e+15
CCC(C(=O)N)N1CCCC1=O,1e+12
CCC(C(=O)N)N1CC(CC1=O)CN=[N+]=[N-],1.25893e+16
CCC(C(=O)N)N1CC(CC1=O)C,7.94328e+14
CCCCCCCCN(C(CC)C(=O)N)C(=O)CC1=CC=C(C=C1)Cl,5.01187e+14
CCC(C(=O)N)N(C(=S)C1CC1)S,1.99526e+15
CCC(C(=O)N)N1C(CCC1=O)C,3.98107e+14
CCC(C(=O)N)N1CCC(C1=O)C,5.01187e+13
CCC(C(=O)N)N1CC(CC1=O)N2N=CC(=[N+]2C)C,3.98107e+13
CCCCC1CC(=O)N(C1)C(CC)C(=O)N,2.51189e+15
CCCC1CC(=O)N(C1)C(CC)C(=O)N,3.98107e+15
CCC(C(=O)N)N1CC(CC1=O)CO[N+](=O)[O-],1e+16
CCC(C(=O)N)N1CC(CC1=O)CSC,7.94328e+15
CCC(C(=O)N)N1CC(CC1=O)NC(=O)OC,6.30957e+14
CCC(C(=O)NC)N1CCCC1=O,7.94328e+13
CCC(C(=N)N)N1CCCC1=O,7.94328e+13
CCC(C(=O)NN)N1CCCC1=O,1.58489e+14
CCC(C(=O)N(C)O)N1CCCC1=O,5.01187e+13
CCCC1CC(=O)N(C1)C(CC)C(=O)N,1e+16
CCC(C(=O)N)N(CC1CCC1)O,1.58489e+14
CCCC(C(=O)N)N1CCCC1=O,1e+12
CCCC(C(=O)N)N1CCCC1=O,1.99526e+14
